Viking Therapeutics, Inc. (NASDAQ:VKTX)
| Market Cap | 4.77B+55.6% |
| Revenue (ttm) | 0 |
| Net Income | -534.80M-211.7% |
| EPS | -4.66-204.6% |
| Shares Out | 116.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,845,648 |
| Open | 37.08 |
| Previous Close | 30.11 |
| Day's Range | 36.34 - 41.73 |
| 52-Week Range | 24.78 - 43.15 |
| Beta | 0.68 |
| Analysts | Buy |
| Price Target | 97.40(+138.43%) |
| Earnings Date | Oct 28, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About VKTX
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
$VKTX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in VKTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VKTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VKTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VKTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VKTX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VKTX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $115.05M |
| XBIState Street SPDR S&P Biotech ETF | $102.90M |
| VBVanguard Morningstar Small-Cap ETF | $83.14M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $47.85M |
| VXFVanguard Extended Market ETF | $44.28M |
| SCHASchwab U.S. Small-Cap ETF | $18.90M |
Estimated from each fund’s disclosed top holdings × AUM
VKTX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from VKTX’s recent data — informational, not investment advice